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Abstract: Oleuropein (Ole), a secoiridoid glucoside present in Olea europaea leaves, gained scientific
interest thanks to its several biological properties, including the anticancer one. We verified whether
Ole might potentiate the cytotoxicity of conventional drugs used to treat melanoma, disclosing
a potentially new therapeutic strategy. We tested the cytotoxic action of Ole alone or in combination
with chemotherapeutics on A375 human melanoma cells. We found that Ole was able, at a dose of
500 µM, to stimulate apoptosis, while at a non-toxic dose of 250 µM, it affected cell proliferation and
induced the downregulation of the pAKT/pS6 pathway. A dose of 250 µM Ole did not potentiate the
effect of Vemurafenib (PLX4032), but it succeeded in increasing the cytotoxic effect of Dacarbazine
(DTIC). The major effect was found in the association between Ole and Everolimus (RAD001), also on
PLX4032-resistant BRAF melanoma cells, which possibly cooperate in the inhibition of the pAKT/pS6
pathway. Of interest, an olive leaf extract enriched in equimolar Ole was more effective and able
to further improve DTIC and RAD001 efficacy on BRAF melanoma cells with respect to Ole alone.
Therefore, Ole represents a natural product able to potentiate a wide array of chemotherapeutics
against BRAF melanoma cells affecting the pAKT/pS6 pathway.
Keywords: BRAF melanoma; chemotherapeutics; extra virgin oil; Oleuropein; olive leaf extract
1. Introduction
Melanoma originates in the skin and although it represents one of the rarer forms of skin
cancer, it underlies the majority of skin cancer-related deaths [1] whose incidence has more than
doubled in the last 10 years. About 50–60% of melanomas show the BRAFV600E mutation [2] where
a valine is replaced by either an arginine (V600K) or glutamic acid (V600E). This mutation implies
the constitutive activation of extracellular signal-regulated kinases (ERK) signaling that leads to
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the increase of proliferation and transformation [2–6]. Although this mutation commonly occurs in
melanoma, it should be noted that the mutation itself is not sufficient to cause cancer since it is also
found in benign melanocytic lesions [1,7,8]. Likewise, the phosphoinositol-3-kinase (PI3K)/protein
kinase B (AKT)/mammalian target of the rapamycin (mTOR) pathway is also involved in melanoma
genesis, and its activation often leads to increased cell survival, proliferation, and motility [9]. Current
protocol for melanoma treatment is dependent on the condition of the tumor at the time of disease
detection; if diagnosed early, melanoma may be removed using surgery, but if it spreads to the lymph
nodes, surgery will be more invasive and chemo- and immunotherapy will be associated with the
treatment. Unfortunately, these therapies may undergo patient resistance and generate host tissue
damage. In particular, intrinsic resistance to apoptosis of melanoma cells is one of the main causes of
anticancer therapy failure. Until recently, the prognosis for advanced malignant melanoma was poor,
but the discovery of the major pathways involved in melanoma progression and resistance prompted
the use of new therapeutic agents.
Therefore, new strategies targeting melanoma cells, which also reduce resistance and patient side
effects, need to be developed and a combination of conventional treatment with biological agents
(the so-called complementary therapy) might be an important breakthrough.
The Mediterranean diet is considered an important preventive instrument against chronic diseases,
such as neurodegenerative and cardiovascular ones, and cancer [10–12]. In particular, epidemiological
studies indicate that the dietary consumption of extra virgin olive oil (EVOO) has a protective effect in
Mediterranean populations [13–16]. EVOO is a functional food with a high level of monounsaturated
fatty acids and a minor level of highly bioactive multiple components, including polyphenols,
to which have been mainly attributed the beneficial effects [17–19]. The phenol composition of
olive oil includes the phenolic alcohols, hydroxytyrosol (HT, 3,4dihydroxyphenylethanol, 3,4-DHPEA,
DOPET), and tyrosol (p-hydroxyphenylethanol, p-HPEA) together with their secoiridoid precursors.
The main secoiridoid in olive oil is 3,4-dihydroxyphenylethanol-elenolic acid (3,4-DHPEA-EA), whose
glycated form is also known as Oleuropein (Ole), the main agent responsible for the bitter taste of
olive leaves and drupes. Ole has been reported to have many pharmacological properties, among
which are antioxidant, anti-inflammatory, cardioprotective, neuroprotective, and hepatoprotective
properties [20,21]. Recently, the accumulating in vitro and in vivo experiments, together with
epidemiological and clinical data, have provided support to the anti-tumor properties of Ole toward
different tumor histotypes, such as breast, colon, and lung cancer [22,23]. Of translational importance
is that Ole was found to be a powerful sensitizer of the Doxorubicin-mediated killing of prostate and
breast cancer cells [24,25]. In fact, it lowers the cytotoxic dose of Doxorubicin, while producing an
anti-proliferative effect in cancer cells.
The aim of our work is to verify both the Ole cytotoxic effect and its cooperation with the current
drugs used in BRAF melanoma. We have found that Ole promotes cytotoxicity of Dacarbazine (DTIC),
a guanine methylating agent, whose treatment, was approved by the Food and Drug Administration
(FDA) and of the mTOR inhibitor Everolimus (RAD001), and that its combination with RAD001 was
also an effective strategy in treating Vemurafenib (PLX4032)-resistant BRAF melanoma cells, where
Vemurafenib (PLX4032) is a BRAF inhibitor. Overall, these findings disclose the wide possibility of
using Ole in the complementary therapy of melanoma.
2. Materials and Methods
2.1. Cell Lines and Culture Conditions
In this study, we used A375 human melanoma cell lines, obtained from American Type Culture
Collection (ATCC, Rockville, MD, USA). In some experiments we used also the human melanoma
cell lines WM266-4 (from ATCC) and M21 (kindly provided by Dr. Antony Montgomery, The Scripps
Research Institute, La Jolla, CA, USA). Melanoma cells were cultivated in Dulbecco’s Modified Eagle
Medium high glucose (DMEM 4500, EuroClone, Milan, Italy) supplemented with 10% fetal bovine
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serum (FBS, Boerhinger Mannheim, Binger Strasse, Ingelheim am Rhein, Germany), at 37 ◦C in
a humidified atmosphere containing 90% air and 10% CO2. Viability of the cells was determined using
a trypan blue exclusion test. Cultures were periodically monitored for mycoplasma contamination
using Chen’s fluorochrome test [26].
A375 melanoma cells resistant to PLX4032 were kindly provided by Laura Poliseno from
University of Pisa and they were obtained as explained in Reference [27]. PLX4032-resistant A375
melanoma cells were maintained without PLX4032 overnight before the start of the experiment.
According to the experiments, cells were treated with Oleuropein glucoside (purity ≥ 90%)
(Extrasynthese S.A., Lyon, Nord-Genay, France), DTIC (Sigma Aldrich, Milan, Italy), RAD001
(MedChem Express, Stockholm, Sweden) or PLX4032 (MedChem Express, Stockholm, Sweden).
2.2. MTT Assay
Cell viability was assessed using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) tetrazolium reduction assay (Sigma Aldrich, Milan, Italy). Cells were plated into 96-multiwell
plates in complete medium without red phenol. The treatment was added to the medium culture
at different doses and times, according to the experiment. Then the MTT reagent was added to the
medium and plates were incubated at 37 ◦C. After 2 h, MTT was removed and the blue MTT-formazan
product was solubilized with dimethyl sulfoxide (DMSO) (Sigma Aldrich, Milan, Italy). The absorbance
of the formazan solution was read at 595 nm using the microplate reader (Bio-Rad Via Cellini, Segrate
(Milan), Italy).
2.3. Sample Preparation for Mass Spectrometry Analysis
Cells were washed with ice-cold phosphate buffered saline (PBS) containing 1 mM Na4VO3,
scraped in PBS, centrifuged for 5 min at 1200 rpm and lysed with ice-cold water. Cells were sonicated
three times for 5 min and supernatants were collected for mass spectrometry analysis.
The samples were measured using analytical High Performance Liquid Chromatography (HPLC)
coupled to API 4000 (AB SCIEX, Toronto, ON, Canada) equipped with the TurboIonSpray source
operated in negative ion mode, as previously described [28] with slight modifications. Briefly,
the capillary voltage of the mass spectrometer was set to −4500 V, the “turbo” gas flow was 10 L/min
of air heated at 400 ◦C. The following transitions were monitored in MRM mode (multiple reaction
monitoring): m/z 153.1 > 123.1 for HT; 377.4 > 307.3 for oleuropein aglycone; 539.5 > 275.3 for Ole.
Optimal CE (collision energy) and CXP (collision cell exit potential) were found at −18 V and −8 V
for HT; −16 V and −6 V for both Oleuropein aglycone and Ole, respectively. The resulting DP
(declustering potential) was −70 V. The chromatographic experiments were undertaken by using
a Series 1290 Infinity LC System (Agilent Technologies, Waldbronn, Germany) HPLC Capillary Pump
coupled to an Agilent Micro ALS autosampler, both being fully controlled from the API 4000 data
system. Liquid chromatography was performed using a Zorbax eclipse C18 3 × 150 mm, 3.5 µm
HPLC column (Agilent Techonologies, Waldbronn, Germany). Column flow was 0.4 mL/min using
a water/acetonitrile (50:50) and 0.05% formic acid in an isocratic elution system. The eluent from the
column was directed to the TurboIonSpray probe without a split ratio.
2.4. Evaluation of Apoptosis
Apoptosis was measured using flow cytometry, using the Annexin V staining. Cells were washed
once with PBS, detached with Accutase (Euroclone, Milan, Italy), resuspended in 100 mL of 1×
Annexin-binding buffer at the concentration of 1 × 106 cells/mL, stained with 5 mL of Annexin V
FITC-conjugated (ImmunoTools, Friesoythe, Germany) and 1 mL of 100 mg/mL propidium iodide (PI)
working solution and incubated at 4 ◦C in the dark condition for 15 min. Then, 400 mL of 1× Annexin
Binding Buffer was added to each sample and cells were analyzed using flow cytometry (BD-FACS
Canto) to find out the viability (annexin V and PI negative, Q3), early apoptosis (annexin V positive
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and PI negative, Q4), or late apoptosis (annexin V and PI positive, Q2). A minimum of 10,000 events
were collected, as previously described [26].
2.5. Cell Cycle Analysis
Cell cycle distribution was analyzed via the DNA content using the PI staining method. Cells
were centrifugated and stained with a mixture of 50 µg/mL PI (Sigma-Aldrich, St. Louis, MO, USA),
0.1% trisodium citrate and 0.1% NP40 (or triton x-100) (Sigma-Aldrich, St. Louis, MO, USA) in the
dark at 4 ◦C for 30 min. The stained cells were analyzed via flow cytometry (BD-FACS Canto, BD
Biosciences, Franklin Lakes, NJ, USA) using red propidium-DNA fluorescence [26].
2.6. Invasion Assay
Cells invasion was performed using a polycarbonate cell culture insert with a pore size of 8.0 µm
(Sigma-Aldrich) coated with Matrigel (0.25 µg/µL; BD Biosciences, Franklin Lakes, NJ, USA). Cells
suspended in 200 µL of their own growth medium were seeded in the upper compartment, while in
the lower chamber, fresh complete medium was added as chemo attractant.
Cells were incubated for 6 h at 37 ◦C, 10% CO2 in air, and 25 µM Ilomastat was used as a control
for metalloprotease inhibition (Millipore, Billerica, MA, USA). After incubation, filters were removed
and the non-invading cells on the upper surface were wiped off mechanically with a cotton swab.
Cells on the lower side of the filters were fixed overnight in ice-cold methanol, then stained using
a DiffQuick kit (BD Biosciences, Franklin Lakes, NJ, USA) and pictures of randomly chosen fields were
taken, as previously reported [26].
2.7. Plate Colony Forming Assay
Approximately 100 cells/mL surviving the different treatments were selected using the trypan
blue exclusion test, seeded in fresh medium, and incubated for 10 days at 37 ◦C. Cells were washed with
PBS, fixed in cold methanol, and stained using a Diff Quik kit (BD Biosciences). The stained colonies
were photographed with a digital camera and the number of colonies in each well was counted.
2.8. Western Blotting Analysis
Cells were lysed and separated using electrophoresis as previously described [26]. Proteins were
transferred to a polyvinylidene difluoride (PVDF) membrane and, subsequently, the membrane was
probed at 4 ◦C overnight with primary antibodies diluted in a solution of 1:1 Odyssey blocking buffer
(LI-COR® Bioscience, Lincoln, NE, USA)/Tween (Sigma-Aldrich, St. Louis, MO, USA) -PBS buffer.
The primary antibodies were: rabbit anti poly (ADP-ribose) polymerase (PARP)1 and cleaved PARP1
(1:1000, Cell signaling Technology, Danvers, MA, USA), rabbit anti-cleaved caspase 3 (1:1000, IDT,
Tema Ricerca, Bologna, Italy), rabbit anti pAKT (1:1000, Cell signaling Technology, Danvers, MA,
USA), rabbit anti AKT (1:1000, Cell signaling Technology, Danvers, MA, USA), rabbit anti pERK
(1:1000, Cell signaling Technology, Danvers, MA, USA), and rabbit anti ERK (1:1000, Cell signaling
Technology, Danvers, MA, USA). The membrane was washed in T-PBS buffer, incubated for 1 h at
room temperature with goat anti-rabbit IgG Alexa Flour 750 antibody or with goat anti-mouse IgG
Alexa Fluor 680 antibody (Invitrogen, Monza, Italy), and then visualized using an Odyssey Infrared
Imaging System (LI-COR® Bioscience, Lincoln, NE, USA). Mouse anti-β-Tubulin monoclonal antibody
(1:1000, Cell signaling Technology, Danvers, MA, USA) was used to control for equal protein loading.
3. Olive Leaf Extract’s Preparation
3.1. Plant Material
Olea europaea L. (cultivar Moraiolo), organic green leaves, were collected in April 2018 in Tuscany
(Vinci, Florence, Italy) and immediately processed.
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3.2. Solvents and Reagents
All the solvents (HPLC grade) and formic acid (ACS reagent) were purchased from Aldrich
Chemical Company Inc. (Milwaukee, WI, USA). Tyrosol, luteolin 7-O-glucoside, chlorogenic, and
Ole were obtained from Extrasynthese S.A. (Lyon, Nord-Genay, France). The HPLC-grade water
was obtained via double-distillation and purification with a Labconco Water Pro PS polishing station
(Labconco Corporation, Kansas City, MI, USA) [29].
3.3. Extraction and Lyophylisation
The extraction using 15% of Olea leaves (45 g leaves/300 g double-distilled and purified water),
was performed in water at a temperature of 50 ◦C for 60 min and at room temperature overnight
(12 h) [29]. The final powder was obtained using lyophilization with the LYOVAC GT 2, with
a freeze-drying yield of 1.85%.
3.4. Sample Preparation for Mass Spectrometry Analysis
The identity of the phenolic compounds of Olea dry extract powder and the composition of
the solution used for the test in vitro, enriched in Oleuropein, was ascertained using data from the
HPLC/DAD and HPLC/MS analyses, in accordance with a previous paper [30].
3.5. Statistical Analysis
Densitometric data are expressed as means ± standard errors of the mean (SEM) depicted using
vertical bars from representative experiment of at least three independent experiments. Statistical
analysis of the data was performed using ANOVA and Tukey’s multiple comparisons test, and p≤ 0.05
was considered statistically significant.
4. Results
4.1. Ole Efficacy on BRAF Melanoma Cells
The effect of Ole on the cell viability was assessed on BRAF mutant (V600E) A375, WM266-4,
and M21 melanoma cells following incubation for 72 h with an Ole concentration, ranging from 50
to 800 µM (corresponding to ≈25–400 µg/mL), using the MTT assay protocol. At 500–800 µM, Ole
induced a very toxic effect that was able to almost totally reduce the viability of all melanoma cell
lines (Figure S1a); at 250 µM (≈125 µg/mL), Ole caused a different but significant decrease of viability
(about 30% in A375, 50% in WM266-4, and 0% in M21 vs. untreated cells). Starting from these results,
for the later experiments we decided to use the A375 melanoma cell line, in which 250 µM Ole showed
an intermediate toxic effect. In consideration of the possibility that the anticancer effects of Ole might
be due to HT or its other metabolites [23,31,32], we performed some experiments to determine the
presence of intracellular phenolic compounds after incubation from 15 min to 72 h with 250 µM Ole in
A375 cells. As shown in Figure S1b, only Ole was detected in the cytoplasm using mass spectrometry
analysis after only 15 min of incubation and was present without being metabolized until the 72nd
hour of exposure (data not shown).
Prompted by the MTT assay results, we verified that by using a dose of 500 µM Ole, and not
250 µM, a significant percentage of A375 melanoma cells (about 90%) underwent apoptosis after
48 h, as demonstrated through the cytofluorimetric technique (Figure S2b). Based on these results,
melanoma cells were exposed for 24–48 h to 250–500 µM Ole and the level of apoptosis, assessed uisng
western blotting of PARP1, confirmed that only 500 µM Ole was able to promote the expression of
a significant level of cleaved PARP1 after 48 h of treatment (Figure S2c). With the aim to verify whether
Ole might potentiate drug efficiency on melanoma cells, we decided to use a non-toxic 250 µM dose,
approximately corresponding to half maximal inhibitory concentration (IC50), previously determined
in our laboratory (data not shown), which affected cell viability, evaluated using MTT (Figure S2a),
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without inducing cell apoptosis. On the other hand, 250 µM Ole reduced the cell proliferation rate of
treated melanoma cells (Figure S2d) and inhibited pAKT/mTOR pathway, assessed by the decrease of
densitometric analysis of AKT/S6 phosphorylation (Figure S2e).
Ole confirmed its anti-cancer role by also reducing cell invasive ability, one of the most important
features of malignant phenotype, which is strongly linked with metastatic progression. A375 cells
were treated with 250 µM Ole for 24 h, and evaluated for their ability to migrate through Matrigel in
their own growth medium, and showed a reduced invasive activity with respect to the untreated cell
(Figure S2f). These results suggested that Ole alone might be effective in treating BRAF melanoma cells,
thus disclosing the possibility to analyze whether this polyphenol may also improve drug efficacy in
advanced melanoma.
4.2. Combination of Ole with Vemurafenib (PLX4032)
First, we decided to investigate whether Ole might potentiate the activity of PLX4032, which is
used for the targeted therapy of BRAFV600E melanoma. Although this drug shows a very high clinical
efficiency in metastatic melanoma patients harboring the BRAF V600E mutation, a wide type of BRAF
melanoma tumors do not respond to PLX4032 or, in some cases, important clinical side effects limit
the use of this drug, such as skin lesions and even cutaneous squamous cell carcinoma. Furthermore,
due to the genetic heterogeneity of melanoma patients, the development of drug resistance represents
a general phenomenon upon PLX4032 treatment. Several mechanisms of resistance to BRAF inhibitors
have been proposed and most of them are based on pAKT/pS6 hyperactivation, the same pathway
affected by Ole. Unfortunately, we did not find any potentiation of Ole on PLX4032 activity on A375
cells, as shown by the results obtained testing cell viability and efficiency to form colonies (Figure 1a,b)
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using a trypan blue exclusion test after 250 µM (≈125 µg/mL) Ole and/or d treatment for 72 h.
(Right) Quantification data of the reduction of colony numbers compared to UT. UT = untreated.
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4.3. Combination of Ole with Dacarbazine (DTIC)
DTIC belongs to the class of DNA-methylation agents and it is considered the main drug for the
treatment of the advanced stage of melanoma. However, the benefit of the treatment with DTIC in 95%
of cases is partial, with a 6-year median survival of 2%. Therefore, new therapeutic approaches need
to be developed to improve chemotherapy efficacy and patient survival. However, treatment based
on the combination of chemotherapy with other cytotoxic drugs has not resulted in response rates of
durable remission, which were enough to increase the median survival of the patients [33].
The combination of 250 µM Ole plus DTIC (270 and 550 µM corresponding to≈50 and 100 µg/mL)
led to a significant decrease in cell viability with respect to the single treatments, particularly evident
at 72 h of incubation (Figure 2a). This finding was confirmed by the level of clonogenicity, suggesting
the effectiveness of Ole plus DTIC in reducing the cloning efficiency of melanoma cells (Figure 2b).
Furthermore, as shown using Western blot and relative densitometric analysis of Figure 2c, combo
treatment elicited a clear expression of cleaved PARP1 and caspase 3, signifying a promotion of
apoptosis on treated cells. Ole, by itself, reduced pAKT expression without any modification in pERK
levels, but when it was added to DTIC, a significant and more pronounced decrease (by around 30%)
in the pAKT/AKT ratio was found (Figure 2c), corroborating the hypothesis of a potential cooperation
of Ole with DTIC in the pAKT pathway inhibition.
Overall, Ole cooperates with DTIC in melanoma treatment, possibly participating in the
down-regulation of pAKT signaling.
4.4. Combination of Ole with Everolimus (RAD001)
In many cancers, including metastatic melanoma, the PI3K/AKT signal transduction pathway
regulates many basic cellular properties. mTOR inhibiting agents, including RAD001, are effective in
inhibiting the PI3K/AKT/mTOR pathway, although several reports indicate that mTOR inhibitors have
limited single-agent activity against melanoma [34]. Further, our recent research effort demonstrates
that RAD001 might overcome PLX4032 resistance acquired via melanoma cells grown under a low
extracellular pH [26]. These indications prompted us to study a possible cooperation between Ole and
RAD001 and we found that Ole is a potent promoter of RAD001 cytotoxicity (Figure 3a), also confirmed
by a significant reduction of cloning efficiency of combo treated melanoma cells compared to single
treatments (Figure 3b). The enhanced cell death after combo treatment correlates with an enhanced
level of cleaved PARP1 and caspase 3, as shown by the densitometric analysis of the Figure 3c. Further,
Ole potentiates the inhibition of pAKT expression exerted via RAD001 at the 10 µM concentration
(9.5 µg/mL) by around 35% (Figure 3c).
In addition, Ole potentiation of RAD001 treatment might be useful to overcome PLX4032
resistance. In order to confirm this phenomenon, we used A375 PLX4032-resistant melanoma cells,
established by Dr. Poliseno [27], during a long period of exposure of A375 cells to PLX4032. These
resistant cells grow and proliferate in the presence of PLX4032 in a similar way to control cells
(Figure 4a). Further, in contrast with the parental A375 cells, which stopped proliferating and
accumulate in the G1 phase of the cell cycle following exposure to PLX4032, resistant cells in the
presence of the same amount of drug did not show any modification in cell cycle distribution (Figure 4b).
Considering signaling pathways, we found that, resistant cells expressed a higher level of AKT/S6
pathway and an unchanged level of pERK differently from PLX4032-treated cells, which instead
underwent a reduction of pERK (at 2 h of treatment) and pS6 (at 24 h of treatment), as shown by the
densitometric analysis of the Figure 4c. When we determined the capacity of RAD001-Ole to affect
resistant cells, we observed a higher percentage of dead cells with respect to that found after the
treatment with RAD001 alone (Figure 4d), suggesting that the special combination of Ole plus RAD001
could represent a new strategy to also treat chronic addicted PLX4032-resistant melanoma cells.
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Figure 2. Ole-Dacarbazine (DTIC) efficacy on A375 melanoma cells. (a) Dose–time response evaluated
via MTT assay. ( ) (Left) Colony Forming Units (CFU) assay of a ive cells lected using a trypan
blue exclusion test after the treatment with 250 µM (≈125 µg/mL) Ol and/or 270 and 540 µM DTIC
(≈50 and 100 µg/mL) for 72 h. (Right) Quantification data of colony numbers compared to UT.
(c) (Left) Representative Western blot of PARP1, cleaved PARP1, cleaved caspase 3, pAKT, AKT, pS6,
S6, pERK, and ERK after a 250 µM Ole treatment and/or 270 and 540 µM DTIC for 48 h. (Right)
Densitometric quantification of the cleaved PARP1, cleaved caspase 3, and of the ratio of pERK/ERK,
pAKT/AKT, and pS6/S6 relative to β-tubulin expression, expressed as a fold increment (%) compared
to UT. * p ≤ 0.05 refers to Ole-DTIC treatment vs. DTIC alone. UT = untreated.
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Figure 3. Ole-Everolimus (RAD001) efficacy on A375 melanoma cells. (a) Dose–time response evaluated
via MTT assay. (b) (Left) Colonies forming units (CFU) assay of alive cells selected using a trypan
blue exclusion test after a 250 µM (≈125 µg/mL) Ole treatment with and/or 10 and 20 µM RAD001
(≈9.5 and 19 µg/mL) for 48 h. (Right) Quantification data of the colony numbers compared to UT.
(c) (Left) Representative Weste n blot of PARP1, cleaved PARP1, cle ved caspase 3, pAKT, AKT, pS6,
S6, pERK, and ERK after 250 µM Ole treatment with and/or 10 and 20 µM RAD001 for 24 h. (Right)
Densitometric quantification of the cleaved PARP1, cleaved caspase 3, and of the ratio of pERK/ERK,
pAKT/AKT, and pS6/S6 relative to β-tubulin expression, expressed as a fold increment (%) compared
to UT. * p ≤ 0.05 refers to Ole-RAD001 treatment vs. RAD001 alone. UT = untreated.
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Figure 4. Characterization of A375 melanoma cells resistant to PLX4032 and effect of Ole-RAD001
treatment on these cells. (a) Cell viability evaluated via MTT assay. Significance refers to the untreated
control. (b) Cell cycle distribution analyzed using FACS. * p ≤ 0.05 vs. UT. (c) Representative Western
blot of pAKT, AKT, pS6, S6, pERK, and ERK in cells treated with PLX4032 2 µM (≈980 ng/mL) for 2 or
24 h. (Right) Densitometric quantification of the ratio of pERK/ERK, pAKT/AKT, and pS6/S6 relative
to β-Tubulin expression. * p ≤ 0.05 refers t UT. (d) Dose–time response evaluated on A375 cells that
were PLX4032-resistant via MTT assay. * p ≤ 0.05 refers to Ole-RAD001 treatment vs. RAD001 alone.
UT = untreated.
4.5. A Freshly Prepared Olive Leaf Extract Potentiates RAD001 Treatment on BRAF Melanoma Cells
This final investigation discloses the possibility that a freshly prepared olive leaf extract enriched
in an equimolar concentration of Ole is endowed with the same or greater ability to potentiate drug
efficacy. Supplement Figure S3 shows the dry extract composition of gre n lea s xtract, enriched
in Ole, with a final conce tration of 51.99% p/p (48.56% of secoiridoids (Oleuropein glucoside an
Oleuropein aglycone), 0.92% hydroxytyrosol, tyrosol and derivatives, 1.93% of flavonoids, 0.57% of
verbascoside and derivatives), while Supplement Figure S4 shows the quali-quantitative analyses of
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the solution obtained using Olea powder extract after the solubilization of 56 mg of powder in 5 mL of
physiological solution and used for the test in vitro.
The extract enriched in an equimolar concentration of Ole was more effective to potentiate DTIC
and especially RAD001 cytotoxicity (Figure 5a) compared to Ole alone (Figures 2a and 3a). As reported
in Figure 5, the best combination in inducing cell death on BRAF A375 melanoma cells was represented
by the Ole-enriched leaf extract, again, with RAD001, as shown via MTT assay and using the clonogenic
assay (Figure 5a,b). This finding confirms previous results, adding a greater potential translation
impact to the clinic.
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OleRAD001/DTIC treatment vs. RAD001/DTIC alone. (b) (Left) Colonies forming units (CFU) assay
of alive cells selected using a trypan blue exclusion test after Ole-enriched leaf extract treatment with
and/or RAD001 for 24 h. (Right) Quantification data of colony numbers with respect to UT. * p ≤ 0.05
refers to Ole-DTIC or Ole-RAD001 treatment compared to DTIC or RAD001 alone. UT = untreated.
5. Discussion
The focus for cancer treatment has been shifted toward strategies of complementary therapy that
are able to overcome the limitation of a si gle-agent treatmen . Rational combina ion approac es
strongly preferr d in order t improve the overall patient progressi n-free survival, vercom
or dela th development of drug resis ance, and reduce the incidence of side effects. This is f
special importance i the t eatment of melanoma, particularly of the advanced metastatic form,
often resistant to most of the current drugs used in the clinic. Further, du to different transcriptio
pathway activation in melanoma cells, sev ral ot er mechanisms of resis ance to BRAF inhibi i
h ve been identified. Melanoma tumor b aring wild-typ BRAF are int insic lly resistant to PLX4032
or Dabrafen b. Targ ting mitogen-activated protein kinase kinase (MEK) was co sidered a potential
mechanism to overcome BRAF resistanc [35], although the most favor ble treatment s hedule and
sequence is still to be defined. Indeed, multiple levels of cross-talk among itogen-activated prot in
Nutrients 2018, 10, 1950 12 of 17
kinase (MAPK) and PI3K/AKT pathways and the possibility that ERK can be phosphorylated by
the pAKT pathway are demonstrated [36,37]. Thus, it is required to also inhibit the AKT pathway in
melanoma cells resistant to MAPK inhibitors [38]. The activation of the PI3K/AKT/mTOR pathway
represents one of the major mechanisms of acquired resistance to both targeted BRAF inhibitors and
DTIC [39,40]. We have found that BRAF melanoma cells exposed to a low extracellular pH medium
acquired a resistance to both BRAF and MEK inhibitors but were still sensitive to the inhibition of
the AKT/mTOR pathway induced by RAD001 [26]. It is possible, on the other hand, that during
a prolonged mTOR inhibition, PI3K would be able to promote an MAPK pathway through RAS
activation. Overall, from these findings emerge the need to use a treatment involving the simultaneous
inhibition of the MAPK and AKT pathways in order to have a better drug efficiency and reduce
drug resistance.
Although this anti-cancer approach appeared very promising, it had not been as successful as
once believed. Indeed, most combined therapies are based on the combination of toxic compounds,
leading to toxicity and unexpected side effects.
Given our previous evidence for the protective role of Ole in neurodegenerative and
cardiovascular diseases [41–44], we have decided to investigate whether Ole might exert some role in
melanoma treatment. The existing studies indicate that Ole expresses a well-demonstrated protective
role against many types of cancer [22]. Most of the studies have investigated the anticancer effects
of Ole on breast cancer, disclosing that the polyphenol may not only decrease cell viability and
proliferation [45] and synergize with Doxorubicin in in vitro and in vivo models [25,46], but also may
reverse resistance toward the chemotherapeutic agent, Trastuzumab [47]. In addition, Ole is effective
in reducing cell proliferation by increasing apoptosis in human colorectal cancer cells [48] and is able
to sensitize the Doxorubicin-mediated killing of prostate cancer cells [24]. Ole also reduces the cell
viability of hepatocarcinoma, pancreatic, thyroid, neuroblastoma, mesothelioma, and glioblastoma
cancer cells [22]. Still to be clarified are the effects of Ole on BRAF human melanoma cells. Here,
we demonstrate for the first time that Ole treatment represents a new non-toxic anti-cancer agent
against BRAF melanoma cells as a suitable promoter of two major agents used in BRAF-resistant
melanoma cells, such as RAD001 and DTIC. In addition, the particular approach of Ole to potentiate
RAD001 was found appropriate to overcome PLX4032 resistance as demonstrated by the use of special
PLX4032-resistant A375 melanoma cells developed in cultures. This finding discloses a complementary
approach to the therapy of BRAF inhibitor-resistant melanoma that harbors hyperactivation of
AKT. Until now, only one study reported the reversing effect of Ole on chemotherapy-induced
resistance [47]. Thus, these findings open up the chance to use Ole as a therapeutic molecule to
improve the anticancer effects of current chemotherapeutics, due to its low toxicity in normal cells as
previously reported [49–51].
A375 melanoma cells, used in our study, like most of human solid cancers (prostate, breast, and
colon cancer), express the glucose transporter proteins GLUT1 and GLUT3 mRNA and protein, which
may likely promote Ole uptake. Hamdi et al. [49] found that the antiproliferative activity of Ole
in normal fibroblasts was reduced by removing the glucose moiety by β-glycosidase. Furthermore
D-glucose and Ole compete for the GLUTs, as it was demonstrated by the co-incubation of human
melanoma cells with an excess of D-glucose, so it is possible that GLUTs are involved in the
transportation of Ole into cancer cells. In this study we found that Ole was present in the cytoplasm of
A375 cells after only 15 min of incubation (Figure S1b), suggesting a fast uptake of Ole inside the cells,
probably due to their higher level of GLUTs compared to the normal ones. This is a very important
aspect that we can exploit in thinking of an Ole topical application directly on tumor cells. However,
we did not exclude the possibility that Ole could enter into the cells using other routes, in particular,
in areas of inflammatory reactions where several mediators are active.
Interestingly, in a very short time (48 h) Ole was able to induce a clear and significant induction of
melanoma cell death, confirmed by an enhancement of markers of apoptosis. Ole affected the viability
of melanoma cells, probably through the inhibition of phosphorylation of AKT and the S6 pathway.
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This finding is in accordance with Liu’s observation [52], which indicates that inhibition of AKT is
the mechanism underlying the pro-apoptotic and anti-invasive process promoted by Ole in glioma
cells and with Yan’s indication [53] about the induction of apoptosis by Ole through the PI3K/AKT
pathway in HepG2 human hepatoma cell line.
Thus, we proceeded to investigate whether Ole blocking the AKT pathway may act in cooperation
with the current chemotherapy treatments and allow for a decrease the doses that often lead to
toxicity and severe side effects. We found that Ole potentiates the cytotoxic effect of DTIC, reducing
the effective dose by 50%; this might be related to an enhanced reduction in AKT phosphorylation.
In parallel experiments, Ole was also able to potentiate an mTOR inhibitor, such as RAD001, which is
also in PLX4032-resistant melanoma cells. In the same way, Ole reduces the effective dose of RAD001
by 50% and this effect was linked to pAKT abrogation. Thus, Ole, by affecting the PI3K/AKT/mTOR
pathway, might represent a new non-toxic agent of interest in the treatment of advanced melanoma.
It is likely that Ole might also boost up the inhibition of mTOR through the AMPK/mTOR pathway,
which in this study was not investigated, but that was suggested by our previous finding and by other
authors [43,54]. In addition, Ole may inhibit tumor angiogenesis and in vivo tumor growth, as recently
found by the studies of Song et al. [55] and Samara et al. [56].
Although the in vitro studies are very promising, they do not consider Ole metabolism
and bioavailability, such that the in vitro used concentrations, despite being in accordance with
literature [25,57–60], could seem far greater than those that could be realistically achieved in
in vivo models.
Ole inevitably undergoes a metabolic process in in vivo models, and after ingestion, its metabolites
are rapidly detected in plasma at different concentrations depending on gender [61]; however, in the
clinic, most agents are typically given via repeated administration that may lead to accumulation [62],
and this is quite close to the high doses used in in vitro experiments.
Furthermore our results suggest that an easily available product as an olive leaf extract enriched
in Ole could be even more effective than Ole alone, probably because of the co-presence of other
polyphenols among HT, which many authors have suggested to be the real active Ole metabolic
product [23,31,32]. Therefore, olive leaf extracts seem to have a powerful anticancer property as
Samet I. et al. [63] and Mijatovic SA et al. [64] have also shown with regard to human chronic
myelogenous leukemia K562 and melanoma cells, respectively, and their mixed phenolic composition
with an enrichment in Ole could be useful to decrease the in vitro doses in order to obtain the same
effect of Ole administration alone at higher concentration.
Nevertheless, polyphenol bioavailability is still a big drawback that many studies try to overcome
through different approaches including the construction of granules containing probiotics and
Olea europaea extract in order to increase polyphenols bioavailability [65], and the synthesis of more
active Ole analogs with various chemical properties [56].
In conclusion, Ole, and even more so olive leaf extracts, exhibited a promising potential as
adjuvant in conventional anticancer therapies. Furthermore, it may reverse the drug resistance of cancer
cells to chemotherapeutics and reduce adverse effects of conventional therapies on nontarget cells.
The limited in vivo animal studies, as recently summarized by two recent reviews [22,66], and
the paucity of in human studies, in particularly randomized controlled clinical trials, still represents
the major drawback. Therefore, preclinical evidence needs to be substantiated by an evidence-based
approach to determine the effective dose and best route of Ole administration on the basis of its
bioavailability [67] and any side effects related to chronic administration.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/12/1950/
s1, Figure S1: Cell viability of A375, WM266-4 and M21 after Ole glucoside (Ole) treatment, Figure S2: Effects of
Ole on A375 melanoma cells, Figure S3: Quali-quantitative data of dry extract powder obtained by Olea green
leaves extract, Figure S4: Quali-quantitative data of solution used for the test in vitro.
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